GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » PB Ratio
中文

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) PB Ratio

: (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-23), Corbus Pharmaceuticals Holdings's share price is $37.83. Corbus Pharmaceuticals Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was $-1.56. Hence, Corbus Pharmaceuticals Holdings's PB Ratio of today is .

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's PB Ratio or its related term are showing as below:

During the past 11 years, Corbus Pharmaceuticals Holdings's highest PB Ratio was 73.61. The lowest was 0.18. And the median was 6.03.

CRBP's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.36
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Corbus Pharmaceuticals Holdings's average Book Value Per Share Growth Rate was -119.70% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 66.30% per year. The lowest was -23.90% per year. And the median was 15.45% per year.

Back to Basics: PB Ratio


Corbus Pharmaceuticals Holdings PB Ratio Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.33 2.73 1.12 0.42 -

Corbus Pharmaceuticals Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 1.86 3.64 96.29 -

Competitive Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's PB Ratio falls into.



Corbus Pharmaceuticals Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Corbus Pharmaceuticals Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=37.83/-1.561
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Corbus Pharmaceuticals Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Executives
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Headlines

From GuruFocus